Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases.
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.06|
|52 Week High||US$1.82|
|52 Week Low||US$5.70|
|1 Month Change||20.47%|
|3 Month Change||27.27%|
|1 Year Change||42.96%|
|3 Year Change||-37.82%|
|5 Year Change||48.72%|
|Change since IPO||-66.17%|
Recent News & Updates
Galectin: Pursuing A Subset In The NASH Space
Galectin failed a phase 2 trial in 2017. However, the trial saw certain interesting features in a subset of patients. Galectin is pursuing this subset in another trial.
|GALT||US Biotechs||US Market|
Return vs Industry: GALT exceeded the US Biotechs industry which returned 25.9% over the past year.
Return vs Market: GALT exceeded the US Market which returned 33.8% over the past year.
Stable Share Price: GALT is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: GALT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company’s lead product candidate is (GR-MD-02) belapectin galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment of psoriasis, and lung and kidney fibrosis.
Is Galectin Therapeutics undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate GALT's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: GALT is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: GALT is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GALT's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GALT is overvalued based on its PB Ratio (16.2x) compared to the US Biotechs industry average (3.2x).
How is Galectin Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GALT is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: GALT is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: GALT is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: GALT is forecast to have no revenue next year.
High Growth Revenue: GALT is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if GALT's Return on Equity is forecast to be high in 3 years time
How has Galectin Therapeutics performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: GALT is currently unprofitable.
Growing Profit Margin: GALT is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: GALT is unprofitable, and losses have increased over the past 5 years at a rate of 2.2% per year.
Accelerating Growth: Unable to compare GALT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GALT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: GALT has a negative Return on Equity (-166.99%), as it is currently unprofitable.
How is Galectin Therapeutics's financial position?
Financial Position Analysis
Short Term Liabilities: GALT's short term assets ($33.3M) exceed its short term liabilities ($6.1M).
Long Term Liabilities: GALT's short term assets ($33.3M) exceed its long term liabilities ($10.2M).
Debt to Equity History and Analysis
Debt Level: GALT's debt to equity ratio (59.8%) is considered high.
Reducing Debt: Insufficient data to determine if GALT's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: GALT has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: GALT has less than a year of cash runway if free cash flow continues to reduce at historical rates of 1.5% each year
What is Galectin Therapeutics's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GALT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GALT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GALT's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GALT's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GALT's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Joel Lewis (51 yo)
Mr. Joel Lewis serves as Chief Executive Officer and President at Galectin Therapeutics, Inc since September 2, 2020 and Director since December 14, 2017. He served as the Managing Director of Shareholder...
CEO Compensation Analysis
Compensation vs Market: Joel's total compensation ($USD1.23M) is about average for companies of similar size in the US market ($USD1.10M).
Compensation vs Earnings: Joel's compensation has increased whilst the company is unprofitable.
Experienced Management: GALT's management team is considered experienced (4.8 years average tenure).
Experienced Board: GALT's board of directors are considered experienced (3.8 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 3.9%.
Galectin Therapeutics Inc.'s employee growth, exchange listings and data sources
- Name: Galectin Therapeutics Inc.
- Ticker: GALT
- Exchange: NasdaqCM
- Founded: 2000
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$240.657m
- Shares outstanding: 59.28m
- Website: https://galectintherapeutics.com
Number of Employees
- Galectin Therapeutics Inc.
- 4960 Peachtree Industrial Boulevard
- Suite 240
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/19 22:08|
|End of Day Share Price||2021/09/17 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.